Novel subtypes of NPM1-mutated AML with distinct outcome

Arvind Singh Mer; Mark D Minden; Benjamin Haibe-Kains; Aaron D Schimmer

doi:10.1080/23723556.2021.1924600

Novel subtypes of NPM1-mutated AML with distinct outcome

Mol Cell Oncol. 2021 Jun 30;8(4):1924600. doi: 10.1080/23723556.2021.1924600. eCollection 2021.

Authors

Arvind Singh Mer^{1

2}, Mark D Minden¹, Benjamin Haibe-Kains^{1

2

3

4

5}, Aaron D Schimmer^{1

2

4}

Affiliations

¹ Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
² Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada.
³ Department of Computer Science, University of Toronto, Toronto, Ontario, Canada.
⁴ Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
⁵ Vector Institute, Toronto, Ontario, Canada.

Abstract

Acute myeloid leukemia (AML) is heterogeneous with one common subtype recognized by the presence of recurrent mutation of nucleophosmin-1 (NPM1). Emerging evidence indicates that within NPM1 mutated AML there is variation in outcome which challenges how best to characterize and treat the individual patient. Our recent findings show that there are two distinct (primitive and committed) subtypes within NPM1 mutated AML patients. These subtypes exhibit specific molecular characteristics, disease differentiation states, patient survival, and differential drug responses.

Keywords: Acute myeloid leukemia; biomarkers; machine learning; subtype; systems biology.

Grants and funding

This work was supported by the Princess Margaret Cancer Foundation, Canadian Institutes of Health Research (CIHR) and the Ontario Institute for Cancer Research (OICR).